Official Journal of the European Union
Judgment of the General Court of 21 December 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE)
(Case T-194/21) (1)
(EU trade mark - Opposition proceedings - International figurative registration designating the European Union - Figurative mark HYALOSTEL ONE - Earlier EU word mark HYALISTIL and earlier figurative mark HyalOne - Earlier international word mark HYALO - Relative ground for refusal - Article 8(1)(b) of Regulation (EU) 2017/1001 - Obligation to state reasons)
Language of the case: English
Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers)
Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and V. Ruzek, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO: Stelis Biopharma Ltd (Karnataka, India)
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 27 January 2021 (Case R 831/2020-5), relating to opposition proceedings between Fidia Farmaceutici and Stelis Biopharma.
Operative part of the judgment
Annuls the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 27 January 2021 (Case R 831/2020-5);
Orders EUIPO to bear its own costs and to pay those incurred by Fidia farmaceutici SpA in connection with the present proceedings.
(1) OJ C 217, 7.6.2021.